Skip to content
Triveni Bio
News

The latest company updates, news, and insights

Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples

Press Release
9.23.2025

Fierce Biotech names Triveni Bio a “Fierce 15” Biotech Company of 2025

Press Release
9.22.2025

Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis

Press Release
5.21.2025

Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders

Press Release
10.2.2024

BioPharmaDive News: With $115M more, Triveni accelerates immune drug work

In the News
10.2.2024

FierceBiotech News: Triveni ropes in $115M series B less than a year after $92M fundraise

In the News
10.2.2024

Stifel 2024 Virtual Immunology and Inflammation Summit

In the News
9.18.2024

Triveni Bio Appoints Bhaskar Srivastava, M.D., Ph.D., as Chief Medical Officer, Announces Key Program Updates

Press Release
6.12.2024

Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors

Press Release
12.13.2023

MedCity News: Biotech Startup Triveni Unveils $92M to Address Barrier to Treating Inflammation

In the News
11.5.2023
Top